New Ways to Heal Arthritis Approach Clinical Stage

 

Stem cells, Bio Scaffolds with 3D Printing Repair Knee

Medicine & Science◆Regenerative Biology◆April 2026

Orthopedic Medicine

The Race to Regrow What Was Lost:
Cartilage Regeneration Enters the Clinic

A landmark Stanford study, a San Diego startup's Phase 1 data, and a global surge in stem cell and gene-editing trials are converging on a long-elusive goal — restoring the tissue that keeps joints moving, without surgery.

Published · April 7, 2026 Peer Review Status · Reported from primary literature

Bottom Line Up Front

The breakthrough: A November 2025 study published in the journal Science found that a protein called 15-PGDH builds up in aging joints and quietly drives cartilage destruction. Blocking it with a drug caused real cartilage — the smooth, load-bearing kind — to grow back in elderly mice and in human knee tissue removed during joint replacement surgery. Where things stand clinically: A San Diego company called Epirium Bio has already tested a pill form of this drug in healthy human volunteers for a different condition (age-related muscle loss) and found it safe. The company is planning a larger human trial for muscle loss in late 2026. A separate trial targeting knee cartilage repair has not yet started, but the Stanford researchers say they hope to launch one soon. The bigger picture: Stem cell injections, lab-grown cartilage, and gene-editing tools are all being tested in various stages of human trials worldwide. No drug or cell therapy that can actually reverse arthritis has been approved by the FDA. For people living with osteoarthritis today, pain relief and joint replacement surgery remain the main options — but the research has never been more promising.

Somewhere inside the worn, thinning cartilage of an aging knee is a population of cells that have simply forgotten how to behave. They are still there. They are still doing their jobs, more or less — maintaining the slippery, shock-absorbing padding that lets a knee bend, pivot, and carry a person's weight for decades. But over time, those cells have slowly shifted from "build and maintain" mode into "break down and inflame" mode, nudged in the wrong direction by proteins that accumulate as we age. The core question driving osteoarthritis research — one that has frustrated doctors and scientists for generations — is whether those cells can be nudged back.

In late 2025, a team at Stanford Medicine reported that the answer may be yes. Their study, published in the journal Science on November 27, 2025, identified a single protein called 15-PGDH (pronounced roughly "15-P-G-D-H") as a key troublemaker in aging joints. When they blocked this protein — in elderly mice, in mice with knee injuries, and in cartilage tissue removed from human patients during knee replacement surgery — the cartilage grew back. Not scar tissue, not a rough substitute, but the genuine smooth cartilage that healthy joints are made of.

The timing of this discovery is fortunate. A San Diego company called Epirium Bio has been testing a drug that does exactly this — blocks 15-PGDH — in human volunteers since early 2025. The drug was originally being developed to treat age-related muscle loss, not arthritis. But because it has already cleared the first round of human safety tests with no serious problems, it has a head start that could shorten the path to testing it in arthritis patients considerably.

An Aging Protein That Silently Destroys Cartilage

The researchers behind the Stanford study had been studying a category of proteins they call "gerozymes" — a term they coined for proteins that accumulate in the body as we age and quietly undermine how our tissues function. Think of them as molecular saboteurs: they become more active over time, and their main effect is to block the body's ability to repair itself. The same Stanford team identified the first of these aging proteins in 2023, in the context of muscles growing weaker with age.

The protein at the center of the cartilage study, 15-PGDH, works by breaking down a repair-signaling molecule called prostaglandin E2 (PGE2). PGE2 is the body's internal signal to maintain and rebuild tissue. As 15-PGDH builds up with age, it destroys more and more of this repair signal — essentially turning down the body's healing volume. Without enough PGE2, cartilage cells shift from maintenance mode to breakdown mode. The joint slowly deteriorates.

Using advanced microscopy and genetic analysis tools, the research team — led by Dr. Nidhi Bhutani and Dr. Helen M. Blau at Stanford, working with partners at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla — found that levels of this protein in knee cartilage were roughly double in old mice compared to young ones. In aged joints, the cartilage cells had changed character: they were producing fewer of the building blocks that keep cartilage healthy and more of the enzymes that eat it away.

"This is a new way of regenerating adult tissue, and it has significant clinical promise for treating arthritis due to aging or injury. We were looking for stem cells, but they are clearly not involved. It's very exciting." — Dr. Helen M. Blau, Stanford Medicine, co-author, Science 2025

When the team gave old mice a drug that blocks 15-PGDH — injected either into the belly or directly into the knee — the cartilage that had thinned and worn down over years began to grow back. What came back was not the rough substitute that forms after most cartilage injuries. It was the genuine smooth, load-bearing cartilage that healthy knees are built from, confirmed by analysis of its protein composition. Mice that had been limping and favoring their injured legs began to walk more normally and put more weight on the treated limb.

In a parallel set of experiments, mice given knee injuries resembling the ACL tears common in athletes were treated with the drug twice a week for four weeks. Those animals were far less likely to develop arthritis afterward. Untreated animals with the same injuries had double the levels of the destructive protein and developed full arthritis within a month.

Perhaps the most striking result involved human tissue. Cartilage removed from patients undergoing total knee replacement surgery — representing the worst-case scenario of end-stage arthritis — was treated with the drug in the laboratory for just one week. Even this severely damaged human tissue showed signs of repair: fewer breakdown signals, and early evidence of genuine cartilage regrowth. Importantly, this happened without introducing any new cells. The drug simply changed how the existing cells behaved, switching them back toward a younger, more constructive state.

From the Lab to Human Testing: Where the Drug Stands Now

The path from these laboratory findings to a pill or injection that arthritis patients can actually receive runs through Epirium Bio, a clinical-stage drug company based in San Diego. Epirium was co-founded by Dr. Blau and has licensed the technology from Stanford University. Its lead drug candidate, called MF-300, is a pill that works by temporarily blocking the 15-PGDH protein, allowing the body's natural repair signal (PGE2) to rise back to healthier levels. It is taken once a day by mouth.

MF-300 Human Trial Timeline (Epirium Bio)

• Dec 2024: FDA gives Epirium permission to begin human testing of MF-300.
• Jan 2025: First human volunteers receive the drug in a safety trial (for age-related muscle loss).
• Jul 2025: All volunteers complete the first round of testing; no serious side effects reported, no one dropped out.
• Sep 2025: Epirium announces the drug is safe, well tolerated, and working as intended in the body.
• Nov 2025: The Stanford Science paper is published, showing the same drug regrows cartilage in aged mice and in human joint tissue tested in the lab.
• Jan 2026: Additional safety testing in older adult volunteers confirms the same positive results.
• Jan 2026: The FDA and Epirium agree on the design of a larger trial. The FDA confirms the study plan is sound and suggests the company may qualify for a faster review process.
• Target late 2026: A larger trial in about 200 patients with muscle loss begins. Participants will be randomly assigned to drug or placebo for 6 months, with neither patients nor doctors knowing who gets which.
• Arthritis trial: The Stanford researchers say they want to test the drug in arthritis patients, but no formal application has been filed and no start date has been set as of April 2026.

The first human trial enrolled 100 healthy volunteers across several different dose levels. Everyone finished the study. All side effects were mild. Lab tests confirmed that the drug was doing what it was supposed to do in the body — raising levels of the repair signal PGE2 in a dose-dependent way — while leaving a clear chemical signature that distinguished treated participants from those who received a dummy pill. The drug's staying power in the body was long enough to support a convenient once-daily dose.

A follow-up round of testing specifically in older adults — the population most likely to eventually need this drug for arthritis — showed the same clean safety profile and the same evidence of activity. Following a formal meeting with the FDA in January 2026 in which regulators reviewed Epirium's plans for the next, larger trial, both sides reached agreement on who should be enrolled, how success will be measured, and how long the study should run. The company is also pursuing a special FDA designation that would give it more frequent access to agency feedback during development and potentially speed up the review process.

The larger 2026 trial will test the drug in patients diagnosed with age-related muscle loss — a condition called sarcopenia that affects roughly a third of Americans over 60 and for which no FDA-approved treatment currently exists. An arthritis-specific trial, testing whether MF-300 can grow back cartilage in human knees the way it did in mice and in lab-dish tissue experiments, remains on the horizon but has not yet formally begun.

Financial disclosure: Drs. Helen M. Blau and Nidhi Bhutani, along with other co-authors of the Science paper, hold Stanford University patents related to this technology. Those patents are licensed to Epirium Bio. Dr. Blau co-founded Epirium and owns equity in the company. These financial ties were disclosed in the published paper and in Stanford's press materials.

The Broader Picture: Stem Cells, 3D Printing, and Gene Editing

The 15-PGDH story is the most exciting recent development, but it is one thread in a much larger tapestry. Researchers around the world have been pursuing the goal of cartilage regeneration through many different routes simultaneously — stem cell injections, engineered scaffolds, 3D-printed tissue, and DNA editing tools. A comprehensive review of this field, published in the World Journal of Stem Cells in September 2025 by orthopedic researchers at Yantaishan Hospital in China, provides a useful map of where each of those routes currently leads.

Why Is Cartilage So Hard to Repair?

To understand why so many approaches are being tried — and why progress has been slow — it helps to understand what makes cartilage uniquely difficult to heal. Unlike most tissues in the body, cartilage has no blood supply and no nerve supply. It gets its nutrients by absorption from the surrounding fluid, the way a sponge soaks up water. This is why cartilage can last for decades without maintenance: it doesn't need blood flow. But it also means that when cartilage is damaged, the body cannot send repair crews the way it would to a broken bone or a cut in the skin. The cartilage cells that are there — called chondrocytes — are mostly dormant and have very limited ability to reproduce or rebuild on their own.

When a joint is stressed by age, injury, or excess weight, these cartilage cells begin releasing inflammatory chemicals and enzymes that eat away at the joint's structural proteins. As the padding thins, the raw ends of bone begin to grind against each other, causing the pain, swelling, and stiffness of osteoarthritis. Over time, the joint becomes deformed. More than 33 million Americans live with this condition; over a million undergo knee or hip replacement every year.

The standard surgical responses to cartilage loss have significant limitations. Microfracture — drilling small holes in the underlying bone to encourage the bone marrow to release repair cells — usually produces a rougher, weaker substitute called fibrocartilage rather than the real thing. Autologous chondrocyte implantation (ACI), in which a patient's own cartilage cells are harvested, grown in a lab, and re-implanted, can work but requires two surgeries, is expensive, and is only suitable for smaller defects. Joint transplants from donor tissue can help but are limited by the supply of suitable donor material.

Stem cells offer a different approach. Stem cells are master cells that can be directed to become many different cell types — including cartilage cells. They also release anti-inflammatory signals that calm down the destructive environment inside an arthritic joint. This dual ability — to build and to calm — makes them attractive candidates for cartilage repair.

Stem Cells from Bone Marrow: The Longest Track Record

The most thoroughly studied type of stem cell for cartilage repair comes from bone marrow — the soft, spongy tissue inside large bones. These are called mesenchymal stem cells, or MSCs for short. Think of them as generalist repair cells that can be coaxed, with the right chemical signals, into becoming cartilage cells.

In a landmark 2004 study by Dr. Wakitani and colleagues, bone marrow stem cells were successfully implanted into damaged cartilage in human kneecaps, producing measurable improvements in both tissue quality and patient function — the first demonstration that this approach could work in a living person. A rigorous randomized controlled trial in 2015 by Vega et al. then showed that injecting these cells directly into an arthritic knee improved pain and cartilage quality on MRI scans compared to hyaluronic acid — a standard lubricating injection — in patients with knee osteoarthritis.

The most impressive long-term data in this area comes from a product called Cartistem, developed in South Korea. Cartistem uses stem cells harvested from umbilical cord blood — donated at birth, with the parents' consent — combined with a gel that holds them in place inside the joint. A clinical trial following patients for seven years found sustained cartilage regeneration, improved joint scores, and no tumors or immune reactions in any patient. Cartistem is approved for use in South Korea but has not received approval from the FDA for use in the United States.

There is an important catch with bone marrow stem cells from older patients: as we age, our own stem cells age too. Cells from elderly donors tend to be less vigorous — they don't multiply as reliably and they don't produce as much repair tissue. This means the people who most need cartilage repair may have the least capable stem cells to work with. Standardized manufacturing processes are helping, but this remains a real challenge.

Stem Cells from Fat: More Accessible, Still Promising

Fat tissue turns out to be an excellent source of stem cells — they are abundant, easily collected through a simple liposuction procedure, and can be used in outpatient settings. Stem cells collected this way are called adipose-derived stem cells, or ADSCs.

A 2019 study by Lee and colleagues found that a single injection of a patient's own fat-derived stem cells into an arthritic knee produced significant improvement in pain and joint function scores at six months, with no serious side effects. A parallel 2019 study by Hong and colleagues showed improved cartilage thickness on MRI scans over twelve months. And a 2025 clinical trial from Thailand compared fat-derived stem cells directly against hyaluronic acid injections in 48 patients with early arthritis: the stem cell group showed measurable cartilage growth on MRI, while the control group continued to lose cartilage.

Fat-derived stem cells also have a known limitation: they have a tendency to overshoot and turn into a bone-like tissue rather than true smooth cartilage, especially when not handled carefully. Researchers are working on protocols to keep them on the right developmental path.

A particularly promising variant involves stem cells harvested from the fat pad just below the kneecap — a small cushion of fatty tissue already inside the joint. These "infrapatellar fat pad" stem cells are native to the joint environment and show a natural tendency to calm inflammation, making them well-suited for intra-articular injection. They are currently in early-stage clinical investigation.

Stem Cells from the Joint Lining: The Joint-Native Option

The lining of a joint — the thin membrane called the synovium — also contains stem cells, and researchers have found that these may be the best-suited of all for cartilage repair. They are already adapted to the joint environment, they have a particularly strong ability to turn into cartilage cells, and they are less prone to the "overshoot" problem that plagues fat-derived cells. Studies in laboratory dishes have confirmed that synovial stem cells show higher cartilage gene activity and less tendency to convert to bone-like tissue compared to bone marrow stem cells.

The drawback is access: harvesting synovial stem cells requires a minor surgical procedure to access the joint lining. They are currently being studied in early clinical research but have not yet been tested in large randomized trials.

Stem Cells Grown from Skin: The Future Off-the-Shelf Option

Perhaps the most scientifically ambitious approach involves a type of cell called induced pluripotent stem cells, or iPSCs. The concept: scientists take ordinary adult cells — a skin cell, a blood cell — and reprogram them using a set of chemical signals that essentially rewind the clock, converting them back into a blank-slate stem cell that can then be directed to become any cell in the body, including a cartilage cell.

The appeal is enormous. iPSCs can in principle be made from a single healthy donor, grown in unlimited quantities, and banked as an off-the-shelf product available to anyone — bypassing the supply-chain problems of approaches that require each patient's own cells. In 2015, Dr. Yamashita and colleagues showed that iPSCs could be converted into cartilage constructs that integrated well into cartilage defects in rats. More recently, the first human test of iPSC-derived cartilage cell sheets was conducted in Japan, finding the approach to be safe with signs of tissue integration over one year.

The main concern regulators have raised is the theoretical risk that any remaining undifferentiated iPSCs in the product could form tumors called teratomas — a risk that requires exhaustive quality testing of every batch. That concern has not materialized in early human testing, but long-term monitoring continues. Scalability and manufacturing cost remain significant practical barriers. Full regulatory approval for an iPSC-based cartilage therapy in the U.S. or Europe is likely still a decade or more away.

Where Each Stem Cell Approach Stands in 2026

• Bone marrow stem cells: Human trials completed; one product (Cartistem) approved in South Korea with 7-year follow-up data. Not FDA-approved in the U.S.
• Fat-derived stem cells: Multiple human trials showing measurable cartilage improvement on MRI. Not FDA-approved.
• Kneecap fat pad stem cells: Early human research underway. Not yet in large trials.
• Joint lining stem cells: Laboratory and small-scale studies only. Not yet in large trials.
• iPSC-derived cartilage cells: First human safety test completed in Japan. Manufacturing cost and scale remain barriers.
• Nasal cartilage cells: A first-in-human safety trial (Mumme et al., Lancet 2016) showed cartilage repair and integration in the knee. Limited follow-on work.
• FDA's official position (2026): No stem cell or regenerative therapy is approved for any orthopedic condition, including osteoarthritis.

What the Regulators Actually Think

A medical policy review updated through July 2025, conducted by a major health insurer examining the full body of published research, found that the evidence for stem cell injections in knee arthritis is not yet strong enough to consider it a standard treatment. A pooled analysis of multiple randomized clinical trials did show statistically significant pain reduction in patients who received stem cell injections — but the studies varied so widely in their methods that the results were hard to compare, and there were signs that positive results were more likely to be published than negative ones. Some individual trials found no significant benefit. Others found only modest effects in patients with more advanced arthritis, where the damage may simply be too extensive for injections to overcome.

The FDA and the Federal Trade Commission issued joint enforcement actions in 2024–2025 against more than 40 commercial clinics that were selling stem cell injections for arthritis and other conditions while making unproven claims about what those treatments could do. This crackdown matters for patients: there is a booming commercial market for stem cell injections that is running far ahead of the scientific evidence. Clinics offering these treatments outside of a registered clinical study are not required to prove their products work. Patients paying $5,000 to $15,000 out of pocket for commercial stem cell injections should be cautious and should verify that the treatment is part of an FDA-registered clinical trial before proceeding.

3D-Printed Cartilage: Building From Scratch

An entirely different approach to the cartilage problem involves building new tissue in the laboratory and then implanting it. Three-dimensional bioprinting — essentially the same idea as a 3D printer, but using living cells mixed into a gel as the "ink" — can create structures that mimic the layered architecture of real cartilage. Researchers have demonstrated that these printed constructs can survive transplantation, integrate with surrounding tissue, and produce the proteins that give cartilage its cushioning properties.

A 2025 advance combined 3D printing with a specially engineered gel that slowly releases growth-promoting chemicals over time, creating miniature cartilage organoids — tiny, lab-grown cartilage units — that repaired defects in animals within eight weeks, with tissue that looked genetically similar to healthy cartilage. AI-assisted software is now being used to optimize the composition of the "bio-ink" and the printing patterns to improve consistency and mechanical strength. 3D-printed cartilage constructs remain preclinical — they have not yet been tested in human joints — but the technology is advancing rapidly.

Gene Editing: Fixing the Problem at Its Source

A tool called CRISPR — often described as "molecular scissors" — allows scientists to edit the DNA inside living cells with high precision, turning specific genes on or off. In the context of cartilage repair, researchers are using CRISPR to address the most frustrating problem in stem cell therapy: the tendency of implanted cells to convert into bone-like tissue rather than staying as smooth cartilage. By switching off the genes that drive this conversion and boosting the genes that maintain cartilage identity, scientists have been able to keep lab-grown cartilage cells in the right state for much longer.

A 2024 study took a different angle: instead of editing cells in the lab before implanting them, researchers used tiny fat bubbles (called lipid nanoparticles — the same technology used to deliver mRNA COVID-19 vaccines) to carry cartilage-promoting genetic instructions directly into the arthritic joint. In animal studies, this approach promoted cartilage growth and slowed arthritis progression. The advantage is significant: it eliminates the need to harvest, culture, and re-implant cells altogether. All the repair instructions are delivered in a single injection.

A related strategy uses biological packets called exosomes — tiny capsules naturally shed by cells, loaded with signaling molecules — as a delivery vehicle. Exosomes derived from stem cells that have been genetically modified to carry extra cartilage-protective signals have shown the ability to promote repair and slow breakdown in animal models. Like the mRNA approach, exosome therapy does not require implanting live cells, which may simplify the regulatory path. Both approaches remain entirely in the preclinical stage as of 2026 — demonstrated in animals but not yet tested in humans.

Why This Is Taking So Long

Given the volume of research and the number of trials underway, one question naturally arises: if so many approaches show promise in the laboratory, why doesn't anyone have an approved treatment yet?

Part of the answer lies in the biology itself. Because cartilage has no blood supply, proving that a treatment actually regenerated real cartilage — rather than just reducing pain — requires imaging tests and sometimes a second arthroscopic look inside the joint. The MRI systems and scoring methods that measure cartilage thickness are not perfectly standardized across hospitals or countries, which makes it hard to compare results from different studies. Some trials show good MRI results without corresponding pain improvement. Others show pain relief without clear structural change. Establishing that a treatment does both, reliably, in a large enough number of patients, takes time and money.

Animal models of arthritis also have limitations. Most are created quickly — by cutting a ligament or injecting a chemical into a joint — producing a faster, more uniform disease than the slow, decades-long degeneration in most human patients. A treatment that reverses quickly induced arthritis in a young rat may face a very different challenge in the 68-year-old knee of a patient who has been walking on damaged cartilage for fifteen years.

"In 2025, the field of cartilage repair stands at the intersection of promising breakthroughs, inflated expectations, and a future rapidly shaped by technological innovation." — Trindade et al., Cartilage Repair in 2025: Hope, Hype, or Horizon?, PMC 2025

For stem cell and gene-based therapies specifically, the regulatory bar is appropriately high — and appropriately slow. The FDA classifies these products as "advanced therapies," requiring exhaustive documentation of safety, manufacturing consistency, and efficacy before approval. Cells grown in a lab have to be tested for purity, potency, freedom from contamination, and consistency from batch to batch. A single failed manufacturing run can jeopardize an entire trial. Insurance companies, for their part, will not cover experimental treatments — which means even patients who want to participate in legitimate trials may face significant out-of-pocket costs.

What Patients Should Know Right Now

For the more than 33 million Americans living with osteoarthritis — and the more than one million who undergo knee or hip replacement every year — the current reality is unchanged by any of this research: no drug, no injection, and no cell therapy has been proven to stop or reverse arthritis. Exercise, weight management, physical therapy, anti-inflammatory medications, and corticosteroid injections remain the mainstay of treatment. Hyaluronic acid injections (sometimes called "gel injections" or "rooster comb shots") provide joint lubrication and modest short-term pain relief in some patients, but results are inconsistent. Platelet-rich plasma (PRP) therapy — injecting a concentrate of a patient's own blood proteins into the joint — has a similarly mixed track record and is usually not covered by insurance.

The commercial stem cell clinics that have proliferated in recent years — advertising intra-articular injections for prices ranging from $5,000 to $15,000 paid directly by the patient — are operating outside the framework of proven medicine. The FDA has been clear: no stem cell product is approved for arthritis. Many of these clinics are making claims that go well beyond what their evidence supports. If you are considering a stem cell treatment, ask for the FDA-issued clinical trial identification number (called an IND number) and look it up at ClinicalTrials.gov to confirm it is a legitimately registered and monitored study.

The legitimate scientific pipeline is genuinely more encouraging today than at any point in the past. The Stanford 15-PGDH discovery is mechanistically coherent, reproducible, and backed by human tissue data. Its commercial partner, Epirium Bio — a San Diego company — has a drug in hand that has already cleared human safety testing and is advancing toward a larger trial. A cartilage-specific human trial, when it starts, will have the benefit of existing human safety data — a meaningful advantage that most drug programs in this space do not enjoy.

The open questions are still formidable. Can a drug or injection actually regenerate enough cartilage in a living arthritic human knee to reduce pain and restore function — and does that effect last? In which patients: early arthritis, post-injury, or late-stage disease? At what cost? Covered by whom? These are the questions that the next five to ten years of clinical trials will need to answer before any of today's discoveries can reach the people who need them most.

Until then, the most accurate statement is also the most frustrating one: the science has never looked more promising — and the finish line is still not yet in sight.

Verified Sources & Formal Citations

1. Singla M, Wang YX, Monti E, et al. Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration. Science. 2026 Mar 5;391(6789):1053–1062. Epub 2025 Nov 27. doi: 10.1126/science.adx6649.
   https://www.science.org/doi/10.1126/science.adx6649 | PubMed: https://pubmed.ncbi.nlm.nih.gov/41308124/
2. Stanford Medicine News. Blocking a master regulator of aging regenerates joint cartilage in mice. November 27, 2025.
   https://med.stanford.edu/news/all-news/2025/11/joint-cartilage-aging.html
3. Stanford Report. Stanford scientists found a way to regrow cartilage and stop arthritis. November 27, 2025.
   https://news.stanford.edu/stories/2025/11/joint-cartilage-aging-osteoarthritis-therapy-research
4. ScienceDaily / Stanford Medicine. Stanford scientists found a way to regrow cartilage and stop arthritis. January 20, 2026.
   https://www.sciencedaily.com/releases/2026/01/260120000333.htm
5. Nature Reviews Drug Discovery. Promoting prostaglandin signalling for joint repair in osteoarthritis. January 5, 2026.
   https://www.nature.com/articles/d41573-025-00209-5
6. Epirium Bio (Business Wire). Epirium Bio Announces Positive Phase 1 Clinical Trial Results Evaluating MF-300 in Healthy Volunteers. September 24, 2025.
   https://www.businesswire.com/news/home/20250924461947/en/
7. Epirium Bio (Business Wire). Epirium Bio Announces Follow-on Phase 1 Results in Older Adult Participants for MF-300. January 8, 2026.
   https://www.businesswire.com/news/home/20260108769777/en/
8. Epirium Bio (Business Wire). Epirium Bio Announces Positive Type C (End-of-Phase 1) Meeting with FDA Supporting Advancement of MF-300 to a Phase 2b Clinical Trial in Sarcopenia. January 27, 2026.
   https://www.businesswire.com/news/home/20260127395210/en/
9. Epirium Bio. Press Releases page (full chronological history of MF-300 program).
   https://epirium.com/press-releases/
10. Epirium Bio (BioSpace). Epirium Bio Completes Dosing in First-In-Human Phase 1 Clinical Trial Evaluating MF-300. July 21, 2025.
    https://www.biospace.com/press-releases/epirium-bio-completes-dosing-in-first-in-human-phase-1-clinical-trial-evaluating-mf-300
11. Tangkanjanavelukul P, Khuangsirikul S, Heebthamai D, et al. Cartilage Regeneration Potential in Early Osteoarthritis of the Knee: A Prospective, Randomized, Open, and Blinded Endpoint Study Comparing Adipose-Derived Mesenchymal Stem Cell (ADSC) Therapy Versus Hyaluronic Acid. Int J Mol Sci. 2025;26(17):8476. doi: 10.3390/ijms26178476.
    https://www.mdpi.com/1422-0067/26/17/8476
12. Trindade R, et al. Cartilage Repair in 2025: Hope, Hype, or Horizon? PMC / NIH. 2025.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC12536974/
13. Cong B, Zhang FH, Zhang HG. Stem cell-based cartilage regeneration: Biological strategies, engineering innovations, and clinical translation. World J Stem Cells. 2025 Sep 26;17(9):108523. doi: 10.4252/wjsc.v17.i9.108523. [Primary source for expanded stem cell section — peer-reviewed, Grade A scientific quality rating, externally peer-reviewed, open access CC BY-NC 4.0.]
    https://www.wjgnet.com/1948-0210/full/v17/i9/108523.htm | PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12476812/
14. Frontiers in Cell and Developmental Biology. Global clinical trial landscape of stem cell-based therapies for osteoarthritis: trends and translational implications. January 6, 2026.
    https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2026.1757935/full
15. Frontiers in Cell and Developmental Biology. Cartilage organoids: an emerging platform for novel osteoarthritis therapies. November 28, 2025.
    https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1668766/full
16. Nature / Experimental & Molecular Medicine. Progressing future osteoarthritis treatment toward precision medicine: integrating regenerative medicine, gene therapy and circadian biology. June 30, 2025. doi: 10.1038/s12276-025-01481-6.
    https://www.nature.com/articles/s12276-025-01481-6
17. medrxiv preprint. Translating CRISPR-Cas Systems into musculoskeletal medicine. September 16, 2025. doi: 10.1101/2025.09.14.25335710.
    https://www.medrxiv.org/content/10.1101/2025.09.14.25335710v1.full.pdf
18. PMC / MDPI. Emerging Strategies in Cartilage Repair and Joint Preservation. Published 2025 Jan. PMC article ID PMC11766557.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC11766557/
19. PMC / Taylor & Francis. Molecular signaling pathways in osteoarthritis and biomaterials for cartilage regeneration. 2025. PMC article ID PMC12064066.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC12064066/
20. Blue Cross Blue Shield of Kansas. Orthopedic Applications of Stem Cell Therapy — Medical Policy Review (literature updated through July 24, 2025). Published February 24, 2026.
    https://www.bcbsks.com/medical-policies/orthopedic-applications-stem-cell-therapy-including-allograft-and-bone-substitute
21. REPROCELL. Current Landscape of FDA Stem Cell Approvals and Trials 2023–2025. September 2, 2025.
    https://www.reprocell.com/blog/current-landscape-of-fda-stem-cell-approvals-and-trials-2023-2025
22. Fight Aging! 15-PGDH Inhibition Spurs Cartilage Regeneration. December 5, 2025.
    https://www.fightaging.org/archives/2025/12/15-pgdh-inhibition-spurs-cartilage-regeneration/
23. ScienceAlert. New Breakthrough to Restore Aging Joints Could Help Treat Osteoarthritis. January 14, 2026.
    https://www.sciencealert.com/new-breakthrough-to-restore-aging-joints-could-help-treat-osteoarthritis
24. Futura Sciences. Stanford scientists found a way to regrow knee cartilage: without surgery or stem cells. February 26, 2026.
    https://www.futura-sciences.com/en/an-anti-aging-injection-could-regenerate-knee-cartilage-and-prevent-osteoarthritis_26231/
25. BioWorld. Cartilage repair study identifies new regeneration mechanism. November 28, 2025.
    https://www.bioworld.com/articles/726648-cartilage-repair-study-identifies-new-regeneration-mechanism
26. Lifespan.io. A Small Molecule Regenerates Cartilage in Aged Mice. January 9, 2026.
    https://lifespan.io/news/a-small-molecule-regenerates-cartilage-in-aged-mice/
27. Oxford Academic / Precision Clinical Medicine. New treatment for osteoarthritis: Gene therapy. June 8, 2023. doi: 10.1093/pcmedi/pbad014.
    https://academic.oup.com/pcm/article/6/2/pbad014/7186940
28. Springer Nature / Bio-Design and Manufacturing. Complexities and challenges associated with articular cartilage tissue defect reconstruction: an overview of bioprinting therapeutics. September 19, 2025.
    https://link.springer.com/article/10.1631/bdm.2400363
29. Wakitani S, Mitsuoka T, Nakamura N, et al. Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. Cell Transplant. 2004;13(6):595–600. doi: 10.3727/000000004783983747. [Foundational first BMSC human cartilage implantation study.]
30. Vega A, Martín-Ferrero MA, Del Canto F, et al. Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial. Transplantation. 2015;99(8):1681–1690. doi: 10.1097/TP.0000000000000678. PMID: 25822648.
31. Lee WS, Kim HJ, Kim KI, Kim GB, Jin W. Intra-Articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Phase IIb, Randomized, Placebo-Controlled Clinical Trial. Stem Cells Transl Med. 2019;8(6):504–511. doi: 10.1002/sctm.18-0122. PMID: 30835956.
32. Hong Z, Chen J, Zhang S, et al. Intra-articular injection of autologous adipose-derived stromal vascular fractions for knee osteoarthritis: a double-blind randomized self-controlled trial. Int Orthop. 2019;43(5):1123–1134. doi: 10.1007/s00264-018-4099-0. PMID: 30109404.
33. Park YB, Ha CW, Lee CH, Yoon YC, Park YG. Cartilage Regeneration in Osteoarthritic Patients by a Composite of Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cells and Hyaluronate Hydrogel: Results from a Clinical Trial for Safety and Proof-of-Concept with 7 Years of Extended Follow-Up. Stem Cells Transl Med. 2017;6(2):613–621. doi: 10.5966/sctm.2016-0157. PMID: 28191757. [Cartistem 7-year safety and efficacy data.]
34. Takao T, Sato M, Fujisawa Y, et al. A novel chondrocyte sheet fabrication using human-induced pluripotent stem cell-derived expandable limb-bud mesenchymal cells. Stem Cell Res Ther. 2023;14:34. doi: 10.1186/s13287-023-03252-4. PMID: 36829201. [First-in-human iPSC chondrocyte sheet safety data, Japan.]
35. Mumme M, Barbero A, Miot S, et al. Nasal chondrocyte-based engineered autologous cartilage tissue for repair of articular cartilage defects: an observational first-in-human trial. Lancet. 2016;388(10055):1985–1994. doi: 10.1016/S0140-6736(16)31658-0. PMID: 27789021.
36. Sun M, Ma B, Pan Z, et al. Targeted Therapy of Osteoarthritis via Intra-Articular Delivery of Lipid-Nanoparticle-Encapsulated Recombinant Human FGF18 mRNA. Adv Healthc Mater. 2024;13:e2400804. doi: 10.1002/adhm.202400804. PMID: 39363784. [mRNA-based OA therapy preclinical proof of concept.]
37. Tao SC, Yuan T, Zhang YL, et al. Exosomes derived from miR-140-5p-overexpressing human synovial mesenchymal stem cells enhance cartilage tissue regeneration and prevent osteoarthritis of the knee in a rat model. Theranostics. 2017;7(1):180–195. doi: 10.7150/thno.17133. PMID: 28042326. [Engineered exosome cartilage repair preclinical study.]
38. FDA Official Position on Stem Cell Therapy in Orthopedics. Via BCBS Kansas Medical Policy (updated Feb 2026), citing FDA guidance: "Regenerative medicine therapies have not been approved for the treatment of any orthopedic condition, such as osteoarthritis."
    https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

Reported from primary literature, press releases, and peer-reviewed sources  |  Scientific American style  |  April 7, 2026  |  All sources verified and URL-linked above